1-(3-(4-cyanophenoxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea | 1400989-25-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-(4-cyanophenoxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea
• 英文别名: Sc-43；1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
• CAS: 1400989-25-4
• 化学式: C₂₁H₁₃ClF₃N₃O₂
• 分子量: 431.801
• InChiKey: QIBWSQJZKMUZAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  74.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氯-5-氨基三氟甲苯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 1-(3-(4-cyanophenoxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity

  摘要：

  Previously, we demonstrated that the multiple kinase inhibitor sorafenib mediates the repression of phospho-STAT3 in hepatocellular carcinoma cells. In this study, we used this kinase-independent mechanism as a molecular basis to use sorafenib as scaffold to develop a novel class of SHP-1-activating agents. The proof of principle of this premise was provided by SC-1, which on replacement of N-methylpicolinamide by a phenylcyano group showed abolished kinase activity while retaining phospho-STAT3 repressive activity. Structural optimization of SC-1 led to compound 6, which repressed phospho-STAT3 through SHP-1 activation and inhibited PLC5 cell proliferation at sub-micromolar potency. In light of the pivotal role of phospho-STAT3 in promoting tumorigenesis and drug resistance, this novel SHP-1-activating agent may have therapeutic relevance in cancer therapy. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.023

文献信息

• [EN] AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME<br/>[FR] AGONISTES DE PROTÉINE TYROSINE PHOSPHATASE-1 CONTENANT UN DOMAINE D'HOMOLOGIE SRC-2 ET PROCÉDÉS DE TRAITEMENT L'EMPLOYANT
  申请人：UNIV NAT TAIWAN

  公开号：WO2013020014A1

  公开（公告）日：2013-02-07

  The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase- 1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.

  本发明提供了式I、II或III的新化合物，这些化合物具有Src同源-2含有蛋白酪氨酸磷酸酶-1（SHP-1）激动剂活性。同时，本发明还提供了使用式I、II或III的化合物进行治疗的方法。
• APPLICATION OF SRC HOMOLOGY REGION 2-CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AGONIST FOR IMPROVING FIBROSIS
  申请人：Chen, Kuen-Feng

  公开号：EP3517108A1

  公开（公告）日：2019-07-31

  The present invention provides an application of an SRC homology region 2-containing tyrosine phosphatase-1 agonist in preparation of drugs for treating and reducing a fibrotic disease. Preferably, the agonist is formula (I) as represented by SC-43; the fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.

  本发明提供了一种含SRC同源区2的酪氨酸磷酸酶-1激动剂在制备治疗和减轻纤维化疾病药物中的应用。优选地，所述激动剂为SC-43所代表的式(I)；所述纤维化疾病为皮肤硬化、心脏纤维化、肺纤维化、肝纤维化、胰腺纤维化或肾纤维化。
• Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
  申请人：Chen Kuen-Feng

  公开号：US10993923B2

  公开（公告）日：2021-05-04

  The present invention provides an application of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in preparation of drugs for treating and reducing a fibrotic disease. The fibrotic disease is skin sclerosis, cardiac fibrosis, pulmonary fibrosis, hepatic fibrosis, pancreatic fibrosis, or renal fibrosis.

  本发明提供了 1-[4-氯-3-(三氟甲基)苯基]-3-[3-(4-氰基苯氧基)苯基]脲在制备治疗和减轻纤维化疾病的药物中的应用。纤维化疾病是皮肤硬化、心脏纤维化、肺纤维化、肝纤维化、胰腺纤维化或肾脏纤维化。
• AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME
  申请人：National Taiwan University

  公开号：EP2739139B1

  公开（公告）日：2019-09-25
• US9090617B1
  申请人：——

  公开号：US9090617B1

  公开（公告）日：2015-07-28